Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap
Int J Tuberc Lung Dis
.
2016 Oct;20(10):1418-1419.
doi: 10.5588/ijtld.16.0485.
Authors
Andrew Nunn
1
,
Conor Tweed
2
Affiliations
1
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK. andrew.nunn@ucl.ac.uk.
2
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
PMID:
27725060
DOI:
10.5588/ijtld.16.0485
No abstract available
Publication types
Letter
Comment
MeSH terms
Antitubercular Agents
Humans
Mycobacterium tuberculosis
Rifampin*
Tuberculosis, Multidrug-Resistant*
Substances
Antitubercular Agents
Rifampin